Giles W. Robinson
St. Jude Children's Research Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Giles W. Robinson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05535166 · Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaSt. Jude Children's Research Hospital · recruiting · Medulloblastoma · principal investigator
- Ph1/Ph2NCT04923126 · SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaSt. Jude Children's Research Hospital · recruiting · Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma · principal investigator
- Ph1NCT04023669 · Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research Hospital · completed · Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory · principal investigator
- Ph1NCT03434262 · SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsSt. Jude Children's Research Hospital · completed · Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neurobiology and Brain Tumor ProgramP30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · fiscal years 2025 · $64,171 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Caregiver Education with Interactive Neurodevelopmental Games to Improve Cognitive and Social-Emotional Outcomes in Infants Undergoing Treatment for MedulloblastomaR21CA280187 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HEATHER M CONKLIN · fiscal years 2024 to 2025Named on NCT05535166
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:01 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 339 citationsRCR 9.4
- Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.Lancet Oncol · 2018208 citationsRCR 7.1
- Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).J Clin Oncol · 2021201 citationsRCR 11.3
- A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.Clin Cancer Res · 2017152 citationsRCR 4.4
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).Neuro Oncol · 2022117 citationsRCR 8.2
- Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.Neuro Oncol · 201980 citationsRCR 3.5
- Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.Clin Cancer Res · 202158 citationsRCR 3.5
- Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.Acta Neuropathol · 202051 citationsRCR 2.5
- Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.Neuro Oncol · 202031 citationsRCR 1.9
- Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.Neuro Oncol · 202325 citationsRCR 2.1